Gene and Cell-Based Therapy in Clinical Medicine¶
Chapter 483 | Part 16: Genes, the Environment, and Disease
KEY CLINICAL POINTS¶
- Gene therapy involves delivering functional genes to correct genetic defects, while gene editing modifies DNA directly using tools like CRISPR/Cas9.
- Approved therapies include lentiviral vectors for β -thalassemia (Zolgensma), AAV vectors for spinal muscular atrophy (Zolgensma), and CAR-T cells for hematologic malignancies.
- Key challenges include insertional mutagenesis, immune responses to vectors, and long-term safety monitoring.
- Non-integrating vectors like AAV are preferred for long-lived cells (e.g., neurons, hepatocytes) to avoid genomic integration risks.
- Clinical trials have demonstrated durable efficacy in diseases like sickle cell anemia and hemophilia, but risks like T-cell lymphoma with CAR-T therapies require careful monitoring.
1. DEFINITION & OVERVIEW¶
Gene therapy involves the introduction of genetic material into a patient's cells to treat or prevent disease. Gene editing modifies DNA directly using molecular tools. Cell-based therapies involve genetically modifying cells (e.g., hematopoietic stem cells) for therapeutic use.
Table 483-1: Characteristics of Commonly Used Gene Delivery Vehicles¶
| FEATURES | VIRAL BASE | NONVIRAL |
|---|---|---|
| Genome | RNA | DNA |
| Cell division requirement | G phase | No |
| Packaging limitation | 8 kb | 5 kb |
| Genome integration | Yes | Poor |
| Main advantages | Persistent gene transfer in transduced tissues | Elicits few inflammatory responses, nonpathogenic |
| Main disadvantages | Might induce oncogenesis in some cases; only used ex vivo | Immunogenic; predominantly targets the liver |
1.1 Gene Therapy vs. Gene Editing¶
Gene therapy delivers functional genes to replace or supplement defective ones. Gene editing (e.g., CRISPR/Cas9) directly modifies DNA sequences to correct mutations. Both approaches aim to address genetic disorders but differ in mechanism and application.
1.2 Clinical Applications¶
Gene therapy is used for monogenic disorders (e.g., spinal muscular atrophy, β -thalas, sickle cell disease) and cancers (e.g., CAR-T cells). Gene editing targets specific DNA sequences to correct mutations or disrupt harmful genes.
2. EPIDEMIOLOGY¶
Gene therapy addresses ultra-rare and common genetic disorders. For example, spinal muscular atrophy (1 in 11,000 births) and sickle cell disease (1 in 360 African Americans) are treated with gene-based therapies. Hemophilia B affects ~1 in 25,000 males.
2.1 Risk Factors¶
Genetic mutations, family history, and environmental exposures (e.g., toxins, radiation) contribute to disease risk. For telomere diseases, age-related telomere attrition is a key factor.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Genetic mutations (e.g., SMN1 deficiency in SMA, β -globin mutations in thalassemia) or telomere dysfunction (e.g., dyskeratosis congenita) underlie disease. Gene editing targets specific DNA sequences to correct mutations or disrupt harmful genes.
3.1 Telomere Biology¶
Telomere attrition leads to genomic instability, contributing to aplastic anemia, cirrhosis, and pulmonary fibrosis. Telomere dysfunction is linked to inherited bone marrow failure syndromes.
4. CLINICAL FEATURES¶
Symptoms vary by disease: aplastic anemia (fatigue, infections), cirrhosis (jaundice, ascites), pulmonary fibrosis (dyspnea), and neurodegenerative disorders (motor deficits). Sickle cell disease presents with vaso-occlusive crises and hemolysis.
4.1 Telomere-Related Diseases¶
Aplastic anemia, cirrhosis, pulmonary fibrosis, and nodular regenerative hyperplasia are associated with telomere attrition. Patients may also develop myeloid malignancies due to insertional mutagenesis.
5. DIFFERENTIAL DIAGNOSIS¶
Distinguish telomere diseases from other causes of marrow failure (e.g., aplastic anemia), liver disease (e.g., viral hepatitis), and pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis). Genetic testing is critical for diagnosis.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic workup includes genetic testing (e.g., SMN1 deletion for SMA), telomere length analysis, and imaging (e.g., HRCT for pulmonary fibrosis). For gene therapy, vector-specific assays and transgene expression levels are monitored.
Table 483-2: Currently Approved Gene and Cell Therapy Products¶
| PRODUCT | INDICATION | AGE GROUP | YEAR FIRST APPROVED | VECTOR | TRANSGENE | TARGET TISSUE |
|---|---|---|---|---|---|---|
| Strimvelis® | ADA-SCID | Pediatric | 2016 | Retroviral | ADA | Hematopoieti c stem cells |
| Yescarta® | R/R B-cell lymphomas | Adult | 2017 | Retroviral | CAR-CD19 | T cells |
| Luxturna® | Retinal dystrophy | Pediatric/Adul t | 2017 | AAV2 | RPE65 | Retinal pigment epithelium |
| Zolgensma® | Spinal muscular atrophy | Pediatric (<2 years) | 2019 | AAV9 | SMN1 | Spinal motor neurons |
| Libmeldy® | Metachromati c leukodystro phy | Pediatric | 2020 | Lentiviral | ARSA | Hematopoieti c stem cells |
| Carvykti® | Multiple myeloma | Adult | 2022 | Lentiviral | BCMA CAR | T cells |
6.1 Molecular Diagnostics¶
Next-generation sequencing (NGS) identifies pathogenic variants. Telomere length measurement via qPCR or flow cytometry assesses telomere attrition.
7. MANAGEMENT & TREATMENT¶
Treatment includes gene therapy (e.g., lentiviral vectors for β -thalassemia), stem cell transplantation, and targeted therapies (e.g., danazol for telomere diseases). CAR-T cells are used for B-cell malignancies.
Table 483-4: Adverse Events in Gene Therapy and Gene Editing¶
| VECTOR OR TREATMENT MODALITY | SYMPTOM OR LABORATORY FINDING | MECHANISM | DOSE DEPENDENCE | MITIGATION STRATEGIES |
|---|---|---|---|---|
| Retroviral or lentiviral vectors | Malignancy | Insertional mutagenesis | Yes for retroviral | Preclinical assessment, long-term monitoring |
| AAV vectors | Thrombotic microangiopathy | Antibody-mediated complement activation | Yes | Complement inhibitors (e.g., eculizumab) |
| Ex vivo genome editing | Off-target cleavage | Guide RNA specificity | Likely | Preclinical testing, long-term follow-up |
| CAR-T therapy | Cytokine release syndrome | Systemic inflammatory response | Possibly | Tocilizumab/corticost eroids |
7.1 Gene Therapy Protocols¶
Ex vivo gene transfer involves isolating HSCs, transducing with vectors, and reinfusing. In vivo delivery uses AAV vectors for long-lived cells (e.g., hepatocytes, neurons).
7.2 Risk Mitigation¶
Monitor for insertional mutagenesis, immune responses, and vector toxicity. Use immunomodulatory agents (e.g., corticosteroids) to manage cytokine release syndrome (CRS).
8. PROGNOSIS & COMPLICATIONS¶
Gene therapy offers durable remission in diseases like β -thalassemia and sickle cell disease. Complications include insertional mutagenesis (e.g., T-cell lymphoma), immune responses, and vector-related toxicity.
8.1 Long-Term Risks¶
Monitoring for secondary malignancies, immune-mediated adverse events, and vector persistence is critical. Annual blood counts and imaging are recommended.
9. SPECIAL CONSIDERATIONS¶
Pregnancy: Avoid gene therapy due to potential fetal risks. Pediatrics: Use of AAV vectors for long-lived cells (e.g., neurons). Elderly: Consider reduced-intensity conditioning for stem cell transplants.
9.1 Telomere Diseases¶
Avoid toxins (e.g., busulfan, amiodarone), radiation, and alcohol. Patients should avoid smoking to reduce pulmonary fibrosis risk.
10. KEY POINTS & CLINICAL PEARLS¶
Gene therapy is transformative for monogenic disorders but requires careful risk-benefit analysis. Lentiviral vectors are preferred for long-lived cells, while AAV vectors are used for non-dividing cells. CAR-T therapies are effective for B-cell malignancies but carry risks of secondary malignancies.